What is the appropriate diagnostic workup for suspected VEXAS syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnostic Workup for VEXAS Syndrome

Suspect VEXAS syndrome in older adult males (typically >50 years) presenting with unexplained macrocytic anemia, refractory systemic inflammation, and features mimicking relapsing polychondritis, vasculitis, or myelodysplastic syndromes, and proceed directly to bone marrow examination with UBA1 genetic testing 1, 2.

Clinical Recognition: When to Test

The SWIM-score provides the most reliable screening tool with 100% sensitivity and superior specificity (65%) compared to other scoring systems 3:

  • Skin involvement (neutrophilic dermatosis, Sweet syndrome-like lesions)
  • Weight loss
  • Inflammation (persistently elevated CRP/ESR despite antimicrobials)
  • Macrocytic anemia

A threshold score of ≥2 warrants genetic testing 3.

Key Clinical Red Flags

Look specifically for this constellation 1, 2, 4:

  • Auricular or nasal chondritis (relapsing polychondritis phenotype)
  • Fever unresponsive to antibiotics but responsive to glucocorticoids
  • Iritis or other ocular inflammation
  • Pulmonary infiltrates or neutrophilic alveolitis
  • Unexplained cytopenias, particularly macrocytic anemia
  • ANCA-negative vasculitis presentations
  • Male sex with adult onset (X-linked disorder)

Diagnostic Algorithm

Step 1: Laboratory Evaluation

Hematologic parameters:

  • Complete blood count: macrocytic anemia is nearly universal
  • Pancytopenia or isolated cytopenias
  • Elevated inflammatory markers (CRP, ESR)

Peripheral blood smear may show 5:

  • Vacuoles in mature neutrophils
  • Immature neutrophils
  • Micronuclei
  • These findings support but do not confirm diagnosis

Step 2: Bone Marrow Examination (Essential)

Bone marrow aspiration and biopsy is mandatory 1, 2, 6. Look for:

  • Cytoplasmic vacuoles in myeloid and erythroid precursors (hallmark finding present in vast majority of cases)
  • Vacuolization of granulocytic, monocytic, and erythroid lineages
  • Dysplastic features (may overlap with MDS)
  • Hypercellularity

Critical pitfall: The presence of vacuoles is highly characteristic but not pathognomonic—genetic confirmation is mandatory 2, 6.

Step 3: Genetic Confirmation (Definitive)

UBA1 sequencing on peripheral blood DNA is the gold standard 1, 3:

  • Sanger sequencing reliably detects UBA1 variants and is sufficient for diagnosis 3
  • Target exon 3, specifically codon 41 (p.Met41Thr, p.Met41Val, p.Met41Leu are canonical variants)
  • Appears as mixed C/T chromatogram peak at codon 41 1
  • Sanger sequencing accurately quantifies variant allele fractions (VAFs) from 0.1 to 0.9 3
  • Next-generation sequencing (NGS) adds no additional diagnostic yield over Sanger sequencing 3

Analytic sensitivity matters: Ensure the laboratory uses methods with adequate sensitivity to detect low-level mosaicism 1.

Rare variants outside the Met41 region exist but are uncommon 2.

Step 4: Exclude Mimics

Rule out 1, 2:

  • Primary autoimmune conditions (though may coexist)
  • Infectious causes (though fever typically fails antimicrobial therapy)
  • Primary MDS without UBA1 mutation
  • Other causes of macrocytic anemia

Monitoring Parameters

Once diagnosed, variant allele fraction (VAF) tracking may correlate with disease activity 3:

  • VAF in blood correlates with CRP levels
  • VAF typically increases over time despite conventional immunosuppression
  • May decrease with azacitidine treatment
  • VEXAS cell concentration shows promise as exploratory marker

Diagnostic Pathway Summary

  1. Screen using SWIM-score (≥2 points)
  2. Examine bone marrow for characteristic vacuolization
  3. Confirm with UBA1 Sanger sequencing on peripheral blood
  4. Quantify VAF for baseline and potential monitoring
  5. Assess for MDS overlap features

The diagnosis requires genetic confirmation—clinical and pathologic features alone are insufficient 2, 6. However, recognition of bone marrow vacuolization is often the decisive clue that prompts appropriate genetic testing 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.